Biocon’s repurposed Itolizumab drug gets DCGI nod for emergency use to treat COVID-19

  • Post comments:0 Comments
Biocon’s repurposed Itolizumab drug gets DCGI nod for emergency use to treat COVID-19

Biocon Biologics has received an emergency use authorisation (EUA) for its monoclonal antibody Itoliuzumab from the Drug Controller General of India (DCGI) to treat cytokine storms – one of the leading causes of death among patients with severe covid-19. It has been observed that the novel coronavirus infection, in certain cases, causes an overproduction of cytokines, which can lead to excessive inflammation, organ failure and eventually death.

It said Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications. Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAb for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19, it added.

Leave a Reply